Steven Cohen's CGEM Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 905,376 shares of Cullinan Therapeutics, Inc. (CGEM) worth $12.87 M, representing 0.02% of the portfolio. First purchased in 2023-Q2, this short-term holding has been held for 5 quarters.
Based on 13F filings, Steven Cohen has maintained this position in CGEM for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 545,214 shares. Largest reduction occurred in Q3 2023, reducing 1,801 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Cullinan Therapeutics (CGEM) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cullinan Therapeutics (CGEM) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +545,214 | Add 151.38% | 905,376 | $14.21 |
| Q4 2025 | +360,162 | New Buy | 360,162 | $10.35 |
| Q4 2023 | -224 | Sold Out | 0 | $0.00 |
| Q3 2023 | -1,801 | Reduce 88.94% | 224 | $9.05 |
| Q2 2023 | +2,025 | New Buy | 2,025 | $10.76 |
Steven Cohen's Cullinan Therapeutics Investment FAQs
Steven Cohen first purchased Cullinan Therapeutics, Inc. (CGEM) in Q2 2023, acquiring 2,025 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Cullinan Therapeutics, Inc. (CGEM) for 5 quarters since Q2 2023.
Steven Cohen's largest addition to Cullinan Therapeutics, Inc. (CGEM) was in Q1 2026, adding 905,376 shares worth $12.87 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 905,376 shares of Cullinan Therapeutics, Inc. (CGEM), valued at approximately $12.87 M.
As of the Q1 2026 filing, Cullinan Therapeutics, Inc. (CGEM) represents approximately 0.02% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Cullinan Therapeutics, Inc. (CGEM) was 905,376 shares, as reported at the end of Q1 2026.